Cancer epigenetics is the investigation into heritable gene expression alterations not involving alterations in the DNA sequence." The session "Cancer Epigenetics" is dedicated to the discussion of how such alterations, such as DNA methylation, histone modification, and non-coding RNAs, play a role in tumor development, progression, and therapy response.
Epigenetic alterations may upregulate oncogenes or repress tumor suppressor genes, leading to uncontrolled cell growth and metastasis. In contrast to mutations in DNA, most epigenetic changes are reversible, presenting new avenues for therapeutic intervention. Therapies that target DNA methylation or histone acetylation are now in various stages of development to reactivate normal gene expression and make tumors sensitive to other therapies.
The session also discusses the potential of epigenetic biomarkers to aid in early cancer detection, prognosis, and individualized therapy. New technologies in epigenomics, such as next-generation sequencing and single-cell analysis, are providing us with greater knowledge of tumor heterogeneity and informing the design of precision medicine approaches.
Participants will learn about the mechanisms of cancer epigenetics, ongoing research, and therapeutic implications. This session highlights the promises of epigenetic alteration targeting to enhance treatment response, prevent resistance, and establish new modalities in cancer treatment.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
